TY - JOUR
T1 - Biological predictors of chemotherapy-induced peripheral neuropathy (CIPN)
T2 - MASCC neurological complications working group overview
AU - Chan, Alexandre
AU - Hertz, Daniel L.
AU - Morales, Manuel
AU - Adams, Elizabeth J.
AU - Gordon, Sharon
AU - Tan, Chia Jie
AU - Staff, Nathan P.
AU - Kamath, Jayesh
AU - Oh, Jeong
AU - Shinde, Shivani
AU - Pon, Doreen
AU - Dixit, Niharkia
AU - D’Olimpio, James
AU - Dumitrescu, Cristina
AU - Gobbo, Margherita
AU - Kober, Kord
AU - Mayo, Samantha
AU - Pang, Linda
AU - Subbiah, Ishwaria
AU - Beutler, Andreas S.
AU - Peters, Katherine B.
AU - Loprinzi, Charles
AU - Lustberg, Maryam B.
N1 - Funding Information:
This project was not specifically funded by any organization, but a couple of the investigators are generally funded by the National Institutes of Health/National Cancer Institute (R01CA211887, R01CACA189947)
Publisher Copyright:
© 2019, Springer-Verlag GmbH Germany, part of Springer Nature.
PY - 2019/10/1
Y1 - 2019/10/1
N2 - Chemotherapy-induced peripheral neuropathy (CIPN) is a common and debilitating condition associated with a number of chemotherapeutic agents. Drugs commonly implicated in the development of CIPN include platinum agents, taxanes, vinca alkaloids, bortezomib, and thalidomide analogues. As a drug response can vary between individuals, it is hypothesized that an individual’s specific genetic variants could impact the regulation of genes involved in drug pharmacokinetics, ion channel functioning, neurotoxicity, and DNA repair, which in turn affect CIPN development and severity. Variations of other molecular markers may also affect the incidence and severity of CIPN. Hence, the objective of this review was to summarize the known biological (molecular and genomic) predictors of CIPN and discuss the means to facilitate progress in this field.
AB - Chemotherapy-induced peripheral neuropathy (CIPN) is a common and debilitating condition associated with a number of chemotherapeutic agents. Drugs commonly implicated in the development of CIPN include platinum agents, taxanes, vinca alkaloids, bortezomib, and thalidomide analogues. As a drug response can vary between individuals, it is hypothesized that an individual’s specific genetic variants could impact the regulation of genes involved in drug pharmacokinetics, ion channel functioning, neurotoxicity, and DNA repair, which in turn affect CIPN development and severity. Variations of other molecular markers may also affect the incidence and severity of CIPN. Hence, the objective of this review was to summarize the known biological (molecular and genomic) predictors of CIPN and discuss the means to facilitate progress in this field.
KW - CIPN
KW - Chemotherapy-induced peripheral neuropathy
KW - Neuropathy
UR - http://www.scopus.com/inward/record.url?scp=85069936053&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85069936053&partnerID=8YFLogxK
U2 - 10.1007/s00520-019-04987-8
DO - 10.1007/s00520-019-04987-8
M3 - Review article
C2 - 31363906
AN - SCOPUS:85069936053
SN - 0941-4355
VL - 27
SP - 3729
EP - 3737
JO - Supportive Care in Cancer
JF - Supportive Care in Cancer
IS - 10
ER -